CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 30 filers reported holding CATABASIS PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $72,000 | -17.2% | 90,300 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $87,000 | -46.3% | 90,300 | -10.9% | 0.00% | -50.0% |
| Q1 2017 | $162,000 | -55.7% | 101,347 | 0.0% | 0.00% | -60.0% |
| Q4 2016 | $366,000 | +15.8% | 101,347 | +97.4% | 0.01% | 0.0% |
| Q3 2016 | $316,000 | +209.8% | 51,347 | +85.4% | 0.01% | +150.0% |
| Q2 2016 | $102,000 | – | 27,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $10,573,000 | 10.68% |
| Clarus Ventures, LLC | 2,752,488 | $10,184,000 | 8.91% |
| Rhenman & Partners Asset Management AB | 345,100 | $1,277,000 | 0.23% |
| SPHERA FUNDS MANAGEMENT LTD. | 203,243 | $752,000 | 0.20% |
| Camber Capital Management LP | 1,000,000 | $3,700,000 | 0.18% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 643,580 | $2,381,000 | 0.09% |
| FT Options LLC | 15,059 | $56,000 | 0.05% |
| FRED ALGER MANAGEMENT, LLC | 86,782 | $321,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 27,700 | $102,000 | 0.00% |
| FIRST NEW YORK SECURITIES LLC /NY | 750 | $2,775,000 | 0.00% |